TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05248230: An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults With Cystic Fibrosis

Sponsor: 4D Molecular Therapeutics · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 30 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$618,000

Rescue Site Savings

+$412,000

Unlock Full NCT05248230 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05248230 Rescue Dossier →